Biologic dose reduction versus standard dosing in psoriasis: what is lost and what is gained?
Abstract
As increasing numbers of patients with psoriasis achieve stable disease control, biologic dose reduction has become an important question in maintenance treatment. This narrative review synthesizes evidence from randomized controlled trials and observational studies to compare the losses and gains of biologic dose reduction versus continued standard dosing in terms of disease control, safety, quality of life, and healthcare costs. Current evidence suggests that dose reduction may reduce the rates of high-level skin clearance, such as Psoriasis Area and Severity Index (PASI) 90 and PASI 100, and increase transient flares and disease fluctuations during maintenance treatment. By contrast, broader PASI-based response criteria may still be met by many patients after dose reduction, but this does not mean that the response achieved under standard dosing was fully preserved. The clearest gains were lower biologic use and short-term treatment costs, while improvements in quality of life or safety have not been demonstrated. Biologic dose reduction should therefore be considered a cautious, individualized strategy, with decisions informed by the magnitude of any efficacy loss, treatment burden, and patient preferences. This may help move long-term psoriasis management toward more precise and personalized treatment.
Related
- Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
- Efficacy of Standard Meropenem Dosing in Healthcare-Associated Meningitis: Is It Universal?
- Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
- Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
- Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
BibTeX
@article{peng2026biologic,
title = {{Biologic dose reduction versus standard dosing in psoriasis: what is lost and what is gained?}},
author = {Xiya Peng and Xueqin Xu and Kun Han and Yu Sun},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1973237},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973237},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Biologic dose reduction versus standard dosing in psoriasis: what is lost and what is gained?
AU - Xiya Peng
AU - Xueqin Xu
AU - Kun Han
AU - Yu Sun
PY - 2026
DA - 2026/11/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1973237
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973237
AB - As increasing numbers of patients with psoriasis achieve stable disease control, biologic dose reduction has become an important question in maintenance treatment. This narrative review synthesizes evidence from randomized controlled trials and observational studies to compare the losses and gains of biologic dose reduction versus continued standard dosing in terms of disease control, safety, quality of life, and healthcare costs. Current evidence suggests that dose reduction may reduce the rates of high-level skin clearance, such as Psoriasis Area and Severity Index (PASI) 90 and PASI 100, and increase transient flares and disease fluctuations during maintenance treatment. By contrast, broader PASI-based response criteria may still be met by many patients after dose reduction, but this does not mean that the response achieved under standard dosing was fully preserved. The clearest gains were lower biologic use and short-term treatment costs, while improvements in quality of life or safety have not been demonstrated. Biologic dose reduction should therefore be considered a cautious, individualized strategy, with decisions informed by the magnitude of any efficacy loss, treatment burden, and patient preferences. This may help move long-term psoriasis management toward more precise and personalized treatment.
SN - 1664-3224
ER -